ADIAL PHARMACEUTICALS, INC. ADIL
are a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction
and related disorders. Our investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol
use disorder ("AUD"). AD04 was investigated in a Phase 3 clinical trial, designated the ONWARD trial, for the potential treatment
of AUD in subjects with certain target genotypes, which were identified using our companion diagnostic genetic test. Based on our analysis
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $2.6M | $3.2M | $1.3M | $2.0M | $8.4M | $5.9M | $4.0M | $368.5K | $182.1K | — |
| SG&A | $5.2M | $5.1M | $5.6M | $8.9M | $9.3M | $5.1M | $4.3M | $6.6M | $813.2K | — |
| Total operating expenses | $7.8M | $8.3M | $6.9M | $10.9M | $19.3M | $10.9M | $8.2M | $7.0M | $995.3K | — |
| Operating income | -$7.8M | -$8.3M | -$6.9M | -$10.9M | -$19.3M | -$10.9M | -$8.2M | -$7.0M | -$995.3K | — |
| Pre-tax income | -$8.0M | -$13.2M | -$7.0M | -$10.8M | -$19.5M | -$10.9M | -$8.6M | -$11.6M | -$1.1M | — |
| Income tax | — | — | — | $502 | $94.1K | — | — | — | — | — |
| Net income | -$7.98T | -$13.20T | -$5.12T | -$12.7M | -$19.4M | -$10.9M | -$8.6M | -$11.6M | -$1.1M | — |
| EPS, basic | -11.93 | -68.01 | -3.60 | -12.71 | -1.04 | — | — | — | — | — |
| EPS, diluted | -11.93 | -68.01 | -3.60 | -12.71 | -1.04 | -0.87 | -0.87 | -2.44 | -0.35 | — |
| Shares, diluted (wtd. avg.) | $668.6K | $194.1K | $1.4M | $1.0M | $18.6M | — | — | $243.2K | $174.3K | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.9M | $3.8M | $2.8M | $4.0M | $6.1M | $4.4M | $6.8M | $3.9M | $18.2K | $88.0K |
| Total current assets | $6.2M | $4.1M | $3.2M | $4.8M | $6.5M | $5.1M | $7.7M | $4.7M | $27.2K | — |
| Property, plant and equipment | — | — | — | $50.4K | $58.1K | — | — | — | — | — |
| Goodwill | — | — | — | $249.0K | $249.0K | — | — | — | — | — |
| Other intangibles | $2.8K | $3.3K | $3.9K | $4.5K | $5.0K | $5.6K | $6.2K | $6.7K | $7.3K | — |
| Total assets | $6.7M | $5.0M | $4.7M | $5.7M | $7.5M | $5.5M | $7.7M | $4.7M | $34.5K | — |
| Accounts payable | $655.2K | $250.1K | $103.3K | $276.4K | $286.2K | $648.7K | $190.2K | $99.7K | $342.1K | — |
| Total current liabilities | $1.4M | $975.9K | $653.1K | $1.8M | $2.7M | $1.5M | $539.1K | $258.0K | $1.0M | — |
| Total liabilities | $1.4M | $975.9K | $653.1K | $2.5M | $4.0M | $1.5M | — | — | — | — |
| Retained earnings | -$90.0M | -$82.0M | -$68.8M | -$63.7M | -$50.9M | -$31.5M | -$20.6M | -$12.0M | -$404.0K | — |
| Total equity | $5.3M | $4.1M | $4.1M | $3.3M | $3.5M | $4.0M | $7.1M | $4.4M | -$997.6K | -$103.5K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.5M | -$6.9M | -$6.8M | -$11.2M | -$11.9M | -$7.6M | -$6.3M | -$2.5M | -$494.9K | — |
| Stock-based compensation | $676.2K | $796.8K | $1.7M | $3.4M | $4.2M | $2.0M | $1.6M | $5.4M | $205.4K | — |
| Capital expenditure | — | — | — | — | $64.6K | — | — | — | — | — |
| Investing cash flow | $150.0K | — | $1.5M | — | -$34.0K | -$350.0K | — | — | $35.1K | — |
| Financing cash flow | $8.5M | $7.8M | $4.1M | $9.1M | $13.6M | $5.6M | $9.2M | $6.3M | $390.0K | — |
| Buybacks | — | — | $1.7K | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-093019.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |